Invention Grant
US08236818B2 Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
失效
取代的咪唑并吡啶衍生物作为黑皮质素-4受体拮抗剂
- Patent Title: Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
- Patent Title (中): 取代的咪唑并吡啶衍生物作为黑皮质素-4受体拮抗剂
-
Application No.: US12530676Application Date: 2008-03-28
-
Publication No.: US08236818B2Publication Date: 2012-08-07
- Inventor: Günther Metz , Holger Deppe , Ulrich Abel , Achim Feurer , Inge Ott , Sonja Nordhoff , Michael Soeberdt , Barbara Hoffmann-Enger , Philipp Weyermann , Hervé Siendt , Christian Rummey , Miroslav Terinek , Marco Henneböhle , Holger Herzner , Cesare Mondadori
- Applicant: Günther Metz , Holger Deppe , Ulrich Abel , Achim Feurer , Inge Ott , Sonja Nordhoff , Michael Soeberdt , Barbara Hoffmann-Enger , Philipp Weyermann , Hervé Siendt , Christian Rummey , Miroslav Terinek , Marco Henneböhle , Holger Herzner , Cesare Mondadori
- Applicant Address: CH Liestal
- Assignee: Santhera Pharmaceuticals (Schweiz) AG
- Current Assignee: Santhera Pharmaceuticals (Schweiz) AG
- Current Assignee Address: CH Liestal
- Agency: Kilyk & Bowersox, P.L.L.C.
- Priority: EP07006422 20070328
- International Application: PCT/EP2008/002498 WO 20080328
- International Announcement: WO2008/116665 WO 20081002
- Main IPC: A61K31/437
- IPC: A61K31/437 ; C07D471/04
Abstract:
The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin-4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amytrophic lateral sclerosis (ALS), anxiety and depression.
Public/Granted literature
- US20100093697A1 Substituted Imidazopyridine Derivatives As Melanocortin-4 Receptor Antagonists Public/Granted day:2010-04-15
Information query
IPC分类:
